Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

This study is ongoing, but not recruiting participants.

First Received on September 12, 2005. Last Updated on January 26, 2012 History of Changes

Sponsor:	University of Rochester
Information provided by (Responsible Party):	University of Rochester
ClinicalTrials.gov Identifier:	NCT00178295

Purpose

Treatment for brain cancer may include radiation therapy. Radiation therapy is the treatment of tumors with X-rays. This study is related to understanding the side effects of radiation treatment for brain tumors.

This study is being conducted by the University of Rochester Cancer Center to compare the extent of side effects of brain cancer treatment with changes in levels of blood proteins called cytokines.

Condition	Intervention
Brain Neoplasm	Radiation: Radiation Therapy

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

Resource links provided by NLM:

MedlinePlus related topics: Brain Cancer Cancer Childhood Brain Tumors

U.S. FDA Resources

Further study details as provided by University of Rochester:

Biospecimen Retention: Samples Without DNA

Blood plasma

Estimated Enrollment:	80
Study Start Date:	November 1999

Intervention Details:

standard of care for the cancer being treated

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patient who are going to receive radiation therapy as part of the treatment for their brain cancer

Criteria

Inclusion Criteria:

Any patient who will be treated to the brain or spinal axis for a CNS tum Patients so treated will be stratified according to whether or not the hypo is included in the treatment fields.
Patients receiving external beam radiation to the brain may also be rece chemotherapy or interferon-beta. (Add. #1, 11-9-95)
Patients receiving high dose rate (stereotactic radiosurgery) are eligible.
Patients must sign a study specific informed consent meeting all federal a guidelines.
Patients of any age, including children, are eligible (Add. #3, 11/25/97).

Exclusion Criteria:

Patients who have a malignancy involving the hypothalamic-pituitary ax
Patients who are not treated with irradiation to the brain or spinal axis.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00178295

Locations

United States, New York
University of Rochester, Dept. Radiation Oncology
Rochester, New York, United States, 14642

Sponsors and Collaborators

University of Rochester

Investigators

Study Chair:	Louis S Constine, MD	Universtiy of Rochester, Dept of Radiation Oncology
Study Chair:	Ralph Brasacchio, MD	University of Rochester, Department of Radiation Oncology

More Information

No publications provided

Responsible Party:	University of Rochester
ClinicalTrials.gov Identifier:	NCT00178295 History of Changes
Other Study ID Numbers:	URCC 11095
Study First Received:	September 12, 2005
Last Updated:	January 26, 2012
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Brain Neoplasms
Neoplasms
Trauma, Nervous System
Central Nervous System Neoplasms
Nervous System Neoplasms

Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Wounds and Injuries

ClinicalTrials.gov processed this record on February 12, 2012